Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve who wrote (152)	11/6/1997 8:28:00 PM
From: tdinovo	Read Replies (1) of 496

Steve, Probably too early to say. For the past year, they have been filling the distribution channel, so earlier quarters are not a good basis for projecting the ultimate growth rate. If memory serves me, they believe they have about 10% market penetration on their approved indication at this point. They are, of course, trying to expand the market from recurrent to primary treatment. So, my guess is you'll see modest growth in that market for the next several quarters. The real important revenue producers are more likely to be associated with Amgen choosing an initial molecule. I believe the number being brandied about is $50 million, although I'm not clear as to whether that's the whole milestone string or just the first payment. In an event, since their is little direct cost associated with it, it will flow directly down to the bottom line. Probably a nice pop. BTW, did you see GLFD jump today. Roughly three times the volume of yesterday's decline and in a generally down biotech market. Apparently, some other large players begged to differ with our momentum friend. Ted

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next